down arrow

Immuno-Biological Laboratories Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3921300004
JPY
1,528.00
-257 (-14.4%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Create Medic Co., Ltd.
Kawamoto Corp.
JMS Co., Ltd.
Techno Medica Co., Ltd.
Precision System Science Co., Ltd.
Immuno-Biological Laboratories Co., Ltd.
3-D Matrix Ltd.
Koken Ltd.
Shigematsu Works Co., Ltd.
Japan Medical Dynamic Marketing, Inc.
ReproCELL, Inc.
Why is Immuno-Biological Laboratories Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 6.24%
  • The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Operating profit has grown by an annual rate 18.65%
3
Positive results in Jun 25
  • DEBT-EQUITY RATIO (HY) Lowest at -44.87 %
  • RAW MATERIAL COST(Y) Fallen by -6.94% (YoY)
  • NET PROFIT(9M) Higher at JPY 233.11 MM
4
With ROE of 16.42%, it has a attractive valuation with a 3.16 Price to Book Value
  • Over the past year, while the stock has generated a return of 227.19%, its profits have risen by 32.9% ; the PEG ratio of the company is 0.6
5
Market Beating performance in long term as well as near term
  • Along with generating 227.19% returns in the last 1 year, the stock has outperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Immuno-Biological Laboratories Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Immuno-Biological Laboratories Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Immuno-Biological Laboratories Co., Ltd.
227.19%
2.09
95.33%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
10.95%
EBIT Growth (5y)
18.65%
EBIT to Interest (avg)
-8.88
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.58
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.25%
ROE (avg)
6.24%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.16
EV to EBIT
19.86
EV to EBITDA
18.49
EV to Capital Employed
4.66
EV to Sales
4.29
PEG Ratio
0.58
Dividend Yield
NA
ROCE (Latest)
23.45%
ROE (Latest)
16.42%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
DEBT-EQUITY RATIO (HY)

Lowest at -44.87 %

RAW MATERIAL COST(Y)

Fallen by -6.94% (YoY

NET PROFIT(9M)

Higher at JPY 233.11 MM

-10What is not working for the Company
INTEREST(HY)

At JPY 0.67 MM has Grown at 12.44%

NET SALES(Q)

Lowest at JPY 211.48 MM

Here's what is working for Immuno-Biological Laboratories Co., Ltd.
Debt-Equity Ratio
Lowest at -44.87 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Profit
Higher at JPY 233.11 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (JPY MM)

Raw Material Cost
Fallen by -6.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Immuno-Biological Laboratories Co., Ltd.
Net Sales
At JPY 211.48 MM has Fallen at -12.75%
over average net sales of the previous four periods of JPY 242.38 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Interest
At JPY 0.67 MM has Grown at 12.44%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
Lowest at JPY 211.48 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."